aripiprazole + clozapine

Aripiprazole + clozapine is a combination of two atypical antipsychotic drugs used primarily in the management of treatment-resistant schizophrenia and other severe psychotic disorders. Clozapine is considered the gold standard for treatment-resistant schizophrenia but may not fully resolve all symptoms, particularly negative or residual symptoms. Aripiprazole, when added to clozapine therapy, has been shown in clinical studies and case reports to improve outcomes for patients who do not respond adequately to clozapine alone. The combination leverages their distinct pharmacological profiles—clozapine acts as an antagonist at dopamine D2 and serotonin 5-HT2A receptors among others, while aripiprazole functions as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A receptors. This dual approach can enhance efficacy without significant pharmacokinetic interactions due to different metabolic pathways[1][3][6]. Clinical evidence suggests this combination reduces rehospitalization risk compared with monotherapy[2], with some data supporting improved negative symptom control[1][3].